WSJ
29 Jun 2026, 05:33 UTC · 4h ago
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
29 Jun 2026, 05:33 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Ipsen has acquired navtemadlin, a drug candidate for rare blood cancer currently in late-stage clinical trials. — Adding a late-stage asset reduces clinical risk and provides a clearer path to commercialization and revenue growth for the oncology pipeline.
+0.40Which stocks this story touches
The company is expanding its oncology pipeline by adding a drug candidate in late-stage clinical trials.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
